Verrica Pharmaceuticals
-
West Chester’s Verrica Pharmaceuticals Doubles Ycanth Revenue After Sales Strategy Shift
After overhauling its sales strategy, West Chester-based Verrica Pharmaceuticals more than doubled revenues from Ycanth, its flagship treatment for skin diseases, compared with last year, writes John George for…
-
With New $50 Million Infusion, West Chester’s Verrica Pharmaceuticals to Retire Debt
West Chester-based Verrica Pharmaceuticals has secured $50 million from a private stock sale, which will allow the company to retire its $35 million OrbiMed debt and finance future business activities,…
-
West Chester-Based Verrica Gets Medication Approval in Japan, Triggering $10M Milestone Payment
The regulatory approval of Verrica Pharmaceuticals‘ Ycanth in Japan has triggered a $10 million milestone payment to the West Chester-based company by its overseas partner,…
-
West Chester-based Verrica Pharmaceuticals Agreement Has Potential for $18 Million Boost
West Chester-based Verrica Pharmaceuticals has amended its licensing agreement with Torii Pharmaceutical of Japan, potentially resulting in an $18 million boost in 2025, writes John…
-
West Chester-based Verrica Pharmaceuticals Expects to Raise $42 Million in Public Stock Offering
West Chester-based Verrica Pharmaceuticals expects to raise $42 million in a public stock offering, following staff reductions and the appointment of a new CEO, writes…
-
West Chester-Based Verrica Pharmaceuticals Restructures to Expand Access for Flagship Product
Verrica Pharmaceuticals is restructuring its sales and operating teams in an effort to reduce costs and expand access to its flagship product, writes John George…
-
West Chester-Based Verrica Finally Gets Approval for Skin Disease Treatment
A West Chester pharmaceutical company finally achieved federal approval of a new drug candidate that treats a contagious skin disease, writes John George for the…
-
West Chester-Based Pharma Company Plans Sale of Shares Worth $32.5 Million
West Chester-based Verrica Pharmaceuticals is expecting to raise $32.5 million from the sale of 750,000 shares of its common stock at $6.75 per share and…
-
West Chester Pharmaceutical Company Seeks Fourth FDA Approval for Skin Treatment
West Chester’s Verrica Pharmaceuticals is seeking FDA approval to market the drug “Ycanth,” which treats a skin condition, writes John George for the Philadelphia Business Journal.…
-
West Chester’s Verrica Pharmaceuticals Nets $8 Million Payment from Its Partner in Japan
West Chester-based Verrica Pharmaceuticals has received a trigger payment of $8 million from its product development partner in Japan after a provision from their licensing…
-
West Chester-Based Pharmaceutical Company Working to Land Second Crack at Approval for Skin Disorder Drug
West Chester-based Verrica Pharmaceuticals has moved closer to getting a second chance at approval for its skin disorder drug, writes John George for the Philadelphia…
-
As Stock Market Hits Low Point, These Chester County Companies Saw Their Stocks Drop the Most
At the start of the week, the stock market entered bear territory for the first time since 2020, further pushing down many local companies that…
-
Dermatology Therapeutics Company Based in West Chester Aims to Raise $30 Million in Public Stock Offering
West Chester-based Verrica Pharmaceuticals is looking to raise around $30 million from its public stock offering, writes John George for The Philadelphia Business Journal. The…
-
FDA Voices Concerns About West Chester-Based Pharma Company’s Lead Drug Candidate
West Chester-based Verrica Pharmaceuticals saw its stock plunge by nearly 22 percent after the FDA voiced concerns about its lead drug candidate, VP-102, writes John…
-
West Chester Pharma Firm’s New Drug May Become Standard of Care for Common Skin Disease
Verrica Pharmaceuticals in West Chester is seeking approval from the Food and Drug Administration for a new drug to treat molluscum contagiosum, a common and…
-
West Chester’s Verrica Pharmaceuticals to Go Public with $75 Million IPO
Verrica Pharmaceuticals, a dermatology company based in West Chester, is planning to go public with an initial public stock offering of $75 million, writes John…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
